{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T09:34:40Z","timestamp":1763458480174,"version":"3.41.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-07116-0","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T23:21:35Z","timestamp":1751412095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A nomogram for predicting the risk of tigecycline-associated drug-induced liver injury in a Chinese population"],"prefix":"10.1038","volume":"15","author":[{"given":"Xin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanpeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huixian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haining","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"2","key":"7116_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/08998280.2006.11928154","volume":"19","author":"ND Greer","year":"2006","unstructured":"Greer, N. D. Tigecycline (Tygacil): the first in the Glycylcycline class of antibiotics. Proc. (Bayl Univ. Med. Cent). 19 (2), 155\u2013161. https:\/\/doi.org\/10.1080\/08998280.2006.11928154 (2006).","journal-title":"Proc. (Bayl Univ. Med. Cent)"},{"issue":"1","key":"7116_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.clinthera.2005.01.007","volume":"27","author":"MW Garrison","year":"2005","unstructured":"Garrison, M. W., Neumiller, J. J. & Setter, S. M. Tigecycline: an investigational Glycylcycline antimicrobial with activity against resistant gram-positive organisms. Clin. Ther. 27 (1), 12\u201322. https:\/\/doi.org\/10.1016\/j.clinthera.2005.01.007 (2005).","journal-title":"Clin. Ther."},{"issue":"1","key":"7116_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s15010-014-0691-4","volume":"43","author":"WR Heizmann","year":"2015","unstructured":"Heizmann, W. R. et al. Clinical efficacy of Tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria. Infection 43 (1), 37\u201343. https:\/\/doi.org\/10.1007\/s15010-014-0691-4 (2015).","journal-title":"Infection"},{"issue":"6","key":"7116_CR4","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s10096-019-03756-z","volume":"39","author":"KS Kechagias","year":"2020","unstructured":"Kechagias, K. S., Chorepsima, S., Triarides, N. A. & Falagas, M. E. Tigecycline for the treatment of patients with Clostridium difficile infection: an update of the clinical evidence. Eur. J. Clin. Microbiol. Infect. Dis. 39 (6), 1053\u20131058. https:\/\/doi.org\/10.1007\/s10096-019-03756-z (2020).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"10","key":"7116_CR5","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1073\/pnas.1216691110","volume":"110","author":"L Jenner","year":"2013","unstructured":"Jenner, L. et al. Structural basis for potent inhibitory activity of the antibiotic Tigecycline during protein synthesis. Proc. Natl. Acad. Sci. U S A. 110 (10), 3812\u20133816. https:\/\/doi.org\/10.1073\/pnas.1216691110 (2013).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"4","key":"7116_CR6","first-page":"240","volume":"46","author":"V Seputiene","year":"2010","unstructured":"Seputiene, V. et al. Tigecycline - how powerful is it in the fight against antibiotic-resistant bacteria? Med. (Kaunas). 46 (4), 240\u2013248 (2010).","journal-title":"Med. (Kaunas)"},{"issue":"6","key":"7116_CR7","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","volume":"135","author":"N Chalasani","year":"2008","unstructured":"Chalasani, N. et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the united States. Gastroenterology 135 (6), 1924\u20131934. https:\/\/doi.org\/10.1053\/j.gastro.2008.09.011 (2008).","journal-title":"Gastroenterology"},{"issue":"7","key":"7116_CR8","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","volume":"148","author":"N Chalasani","year":"2015","unstructured":"Chalasani, N. et al. Features and outcomes of 899 patients with Drug-Induced liver injury: the DILIN prospective study. Gastroenterology 148 (7), 1340\u201352e7. 10.1053\/ j.gastro.2015.03.006 (2015).","journal-title":"Gastroenterology"},{"issue":"1","key":"7116_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s12879-022-07258-w","volume":"22","author":"X Shi","year":"2022","unstructured":"Shi, X., Lao, D., Xu, Q., Li, X. & Lv, Q. A case report of drug-induced liver injury after Tigecycline administration: histopathological evidence and a probable causality grading as assessed by the updated RUCAM diagnostic scale. BMC Infect. Dis. 22 (1), 368. https:\/\/doi.org\/10.1186\/s12879-022-07258-w (2022).","journal-title":"BMC Infect. Dis."},{"key":"7116_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejim.2021.10.035","volume":"97","author":"HK Bj\u00f6rnsson","year":"2022","unstructured":"Bj\u00f6rnsson, H. K. & Bj\u00f6rnsson, E. S. Drug-induced liver injury: pathogenesis, epidemiology, clinical features, and practical management. Eur. J. Intern. Med. 97, 26\u201331. https:\/\/doi.org\/10.1016\/j.ejim.2021.10.035 (2022).","journal-title":"Eur. J. Intern. Med."},{"issue":"Suppl 6","key":"7116_CR11","doi-asserted-by":"publisher","first-page":"s104","DOI":"10.7861\/clinmedicine.16-6-s104","volume":"16","author":"D Katarey","year":"2016","unstructured":"Katarey, D. & Verma, S. Drug-induced liver injury. Clin. Med. (Lond). 16 (Suppl 6), s104\u2013s109. https:\/\/doi.org\/10.7861\/clinmedicine.16-6-s104 (2016).","journal-title":"Clin. Med. (Lond)"},{"key":"7116_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ijid.2022.04.024","volume":"120","author":"Z Yu","year":"2022","unstructured":"Yu, Z. et al. Prevalence and risk factors of tigecycline-associated liver injury: A multicenter retrospective study. Int. J. Infect. Dis. 120, 59\u201364. https:\/\/doi.org\/10.1016\/j.ijid.2022.04.024 (2022).","journal-title":"Int. J. Infect. Dis."},{"key":"7116_CR13","doi-asserted-by":"publisher","first-page":"761167","DOI":"10.3389\/fphar.2021.761167","volume":"12","author":"X Shi","year":"2021","unstructured":"Shi, X. et al. Real-World data of Tigecycline-Associated Drug-Induced liver injury among patients in china: A 3-year retrospective study as assessed by the updated RUCAM. Front. Pharmacol. 12, 761167. https:\/\/doi.org\/10.3389\/fphar.2021.761167 (2021).","journal-title":"Front. Pharmacol."},{"issue":"11","key":"7116_CR14","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/jcph.2099","volume":"62","author":"T Jiang","year":"2022","unstructured":"Jiang, T. et al. Risk factors for Tigecycline-Associated hepatotoxicity in patients in the intensive care units of 2 tertiary hospitals: A retrospective study. J. Clin. Pharmacol. 62 (11), 1426\u20131434. https:\/\/doi.org\/10.1002\/jcph.2099 (2022).","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"7116_CR15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul, M. et al. European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin. Microbiol. Infect. 28 (4), 521\u2013547. https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025 (2022).","journal-title":"Clin. Microbiol. Infect."},{"issue":"1","key":"7116_CR16","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1080\/22221751.2019.1601031","volume":"8","author":"H Liu","year":"2019","unstructured":"Liu, H. et al. Detection and characterization of Tigecycline heteroresistance in E. cloacae: clinical and Microbiological findings. Emerg. Microbes Infect. 8 (1), 564\u2013574. https:\/\/doi.org\/10.1080\/22221751.2019.1601031 (2019).","journal-title":"Emerg. Microbes Infect."},{"issue":"12","key":"7116_CR17","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s00134-015-4079-4","volume":"41","author":"J Garnacho-Montero","year":"2015","unstructured":"Garnacho-Montero, J. et al. Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Med. 41 (12), 2057\u20132075. https:\/\/doi.org\/10.1007\/s00134-015-4079-4 (2015).","journal-title":"Intensive Care Med."},{"issue":"2","key":"7116_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/14740338.2017.1270264","volume":"16","author":"I Kyriakidis","year":"2017","unstructured":"Kyriakidis, I., Tragiannidis, A., Munchen, S. & Groll, A. H. Clinical hepatotoxicity associated with antifungal agents. Expert Opin. Drug Saf. 16 (2), 149\u2013165. https:\/\/doi.org\/10.1080\/14740338.2017.1270264 (2017).","journal-title":"Expert Opin. Drug Saf."},{"issue":"10325","key":"7116_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399 (10325), 629\u2013655. https:\/\/doi.org\/10.1016\/S0140-6736(21)02724-0 (2022).","journal-title":"Lancet"},{"issue":"8","key":"7116_CR20","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.cmi.2019.03.014","volume":"25","author":"ET Piperaki","year":"2019","unstructured":"Piperaki, E. T., Tzouvelekis, L. S., Miriagou, V. & Daikos, G. L. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clin. Microbiol. Infect. 25 (8), 951\u2013957. https:\/\/doi.org\/10.1016\/j.cmi.2019.03.014 (2019).","journal-title":"Clin. Microbiol. Infect."},{"issue":"Suppl 1","key":"7116_CR21","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.cmi.2015.11.004","volume":"22","author":"XDR Chinese","year":"2016","unstructured":"Chinese, X. D. R. & Consensus Working Group. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement. Clin. Microbiol. Infect. 22 (Suppl 1), S15\u201325. https:\/\/doi.org\/10.1016\/j.cmi.2015.11.004 (2016).","journal-title":"Clin. Microbiol. Infect."},{"issue":"12","key":"7116_CR22","doi-asserted-by":"publisher","first-page":"e20115","DOI":"10.7759\/cureus.20115","volume":"13","author":"R Pata","year":"2021","unstructured":"Pata, R., Dolkar, T., Patel, M. & Nway, N. Voriconazole-Induced acute liver injury: A case report. Cureus 13 (12), e20115. https:\/\/doi.org\/10.7759\/cureus.20115 (2021).","journal-title":"Cureus"},{"issue":"15","key":"7116_CR23","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1177\/1535370216658144","volume":"241","author":"AM Clark","year":"2016","unstructured":"Clark, A. M., Ma, B., Taylor, D. L., Griffith, L. & Wells, A. Liver metastases: microenvironments and ex-vivo models. Exp. Biol. Med. (Maywood). 241 (15), 1639\u20131652. https:\/\/doi.org\/10.1177\/1535370216658144 (2016).","journal-title":"Exp. Biol. Med. (Maywood)"},{"issue":"2","key":"7116_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1055\/s-0034-1375957","volume":"34","author":"R Bahirwani","year":"2014","unstructured":"Bahirwani, R. & Reddy, K. R. Drug-induced liver injury due to cancer chemotherapeutic agents. Semin Liver Dis. 34 (2), 162\u2013171. https:\/\/doi.org\/10.1055\/s-0034-1375957 (2014).","journal-title":"Semin Liver Dis."},{"issue":"1","key":"7116_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrgastro.2016.168","volume":"14","author":"P Strnad","year":"2017","unstructured":"Strnad, P., Tacke, F., Koch, A. & Trautwein, C. Liver - guardian, modifier and target of sepsis. Nat. Rev. Gastroenterol. Hepatol. 14 (1), 55\u201366. https:\/\/doi.org\/10.1038\/nrgastro.2016.168 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"7116_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1872-034X.2012.01069.x","volume":"43","author":"H Kobashi","year":"2013","unstructured":"Kobashi, H., Toshimori, J. & Yamamoto, K. Sepsis-associated liver injury: incidence, classification and the clinical significance. Hepatol. Res. 43 (3), 255\u2013266. https:\/\/doi.org\/10.1111\/j.1872-034X.2012.01069.x (2013).","journal-title":"Hepatol. Res."},{"key":"7116_CR27","doi-asserted-by":"publisher","first-page":"e17091","DOI":"10.1097\/MD.0000000000017091","volume":"98","author":"J Gong","year":"2019","unstructured":"Gong, J. et al. Efficacy and safety of high-dose Tigecycline for the treatment of infectious diseases: A metaanalysis. Med. (Baltim). 98, e17091. https:\/\/doi.org\/10.1097\/MD.0000000000017091 (2019).","journal-title":"Med. (Baltim)."},{"key":"7116_CR28","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s12325-020-01235-y","volume":"37","author":"L Zha","year":"2020","unstructured":"Zha, L. et al. Effectiveness and safety of high dose Tigecycline for the treatment of severe infections: A systematic review and Meta-Analysis. Adv. Ther. 37, 1049\u20131064. https:\/\/doi.org\/10.1007\/s12325-020-01235-y (2020).","journal-title":"Adv. Ther."},{"key":"7116_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/cc13942","volume":"18","author":"J Garnacho-Montero","year":"2014","unstructured":"Garnacho-Montero, J. & Ferr\u00e1ndiz-Mill\u00f3n, C. High dose of Tigecycline for extremely resistant Gram-negative pneumonia: yes, we can. Crit. Care. 18, 157. https:\/\/doi.org\/10.1186\/cc13942 (2014).","journal-title":"Crit. Care"},{"key":"7116_CR30","unstructured":"National Cancer Institute, National Institutes of Health, US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. (2017). https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf.Published Accessed September 19, 2024."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07116-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07116-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07116-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T23:21:36Z","timestamp":1751412096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07116-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7116"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07116-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22593"}}